Vaccitech plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VACC research report →
Price Chart
About the company
Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing cutting-edge T-cell immunotherapeutics and vaccines. Their mission is to treat and prevent a variety of infectious diseases and cancers. The company's therapeutic pipeline includes several programs undergoing clinical evaluation: VTP-300 is in Phase 1/2a clinical trials for chronic hepatitis B.
- CEO
- William J. Enright MBA
- IPO
- 2021
- Employees
- 33
- HQ
- Oxford, GB
Get TickerSpark's AI analysis on VACC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $192.73M
- P/E
- -0.59
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.44
- EV/EBITDA
- 0.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.18%
- ROIC
- -61.15%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+0.0%
- Op Income
- $506.00K
- Net Income
- $-66,428,000-8.8%
- EPS
- $-1.64-5.8%
- OCF Growth
- -65.8%
- FCF Growth
- -61.0%
- 52W High
- $5.10
- 52W Low
- $1.64
- 50D MA
- $3.14
- 200D MA
- $2.58
- Beta
- -0.27
- RSI (14)
- 50
- Avg Volume
- 731.88K
No earnings-call transcripts are available for VACC yet.
- Free Float
- 73.4%
- Shares Outstanding
- 38.55M
- Float Shares
- 28.30M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| M&G Investment Management Ltd | 5.20M | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 24 | Pelletier Nadege | other | 105,000 |
| Jan 2, 24 | Griffiths Graham | other | 96,500 |
| Jan 2, 24 | Enright William | other | 443,981 |
| Jan 2, 24 | Brown Gemma | other | 193,000 |
| Jun 26, 23 | Scheeren Joseph | buy | 10,000 |
| May 25, 23 | Wright Robin | buy | 13,750 |
| May 11, 23 | Wright Robin | other | 19,197 |
| May 11, 23 | Scheeren Joseph | other | 19,197 |
| May 11, 23 | Phillips Anne M. | other | 19,197 |
| May 11, 23 | Morgon Pierre A. | other | 19,197 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VACC coverage
Recent articles, reports, and earnings notes.
No research on VACC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VACC report →Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
globenewswire.com · Nov 6
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
globenewswire.com · Sep 13
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
globenewswire.com · Aug 10
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
globenewswire.com · Jun 21
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
investorplace.com · Apr 5
Vaccitech to Present at Upcoming October Investor & Scientific Conferences
globenewswire.com · Oct 3
Vaccitech to Present at Upcoming September Investors Conferences
globenewswire.com · Sep 7
Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why
zacks.com · Sep 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.